Xeloda as first-line therapy of metastatic colorectal cancer-our experience
BACKGROUND: Results of phase III clinical studies comparing efficacy of Xeloda vs. standard 5-FU/FA protocols as first line therapy of metastatic colorectal carcinoma (MCRC), have shown better efficacy of Xeloda, with less toxic adverse effects, apart from handfoot syndrome. METHODS: From January 20...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Institute of Oncology, Sremska Kamenica, Serbia
2002-01-01
|
| Series: | Archive of Oncology |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0354-7310/2002/0354-73100204249K.pdf |